PANGRAF 0.5MG CAP

About

Tacrolimus is a highly potent calcineurin inhibitor immunosuppressant, extensively employed in transplant medicine to prevent organ rejection following allogeneic transplantation, encompassing kidney, liver, heart, and lung transplants. Its primary mechanism involves binding to an intracellular protein, FKBP-12, and the resulting complex then inhibits calcineurin, a phosphatase enzyme critical for the activation of T-lymphocytes. By blocking calcineurin, tacrolimus effectively prevents the transcription of various cytokine genes, such as interleukin-2, which are essential for T-cell proliferation and activation. This suppression of the cellular immune response significantly reduces the body's ability to mount an attack against the transplanted organ. Due to its narrow therapeutic index, tacrolimus requires meticulous therapeutic drug monitoring to ensure optimal blood concentrations, thereby maximizing its immunosuppressive efficacy while mitigating the risk of dose-dependent toxicities. It forms a foundational component of many modern immunosuppressive protocols, often combined with other agents to achieve comprehensive immune modulation.

Uses

• Prevention of organ rejection in kidney transplant recipients.
• Prevention of organ rejection in liver transplant recipients.
• Prevention of organ rejection in heart transplant recipients.
• Prevention of organ rejection in lung transplant recipients.

Directions For Use

Take exactly as prescribed by your doctor, usually once or twice daily, on an empty stomach. Swallow capsules whole.

Benefits

• Highly effective in preventing acute rejection episodes.
• Improves long-term graft and patient survival.
• Allows for steroid-sparing regimens.
• Available in immediate and extended-release forms.
• Well-established efficacy in various organ transplants.
• Can be used in combination with other immunosuppressants.

Side Effects

• Tremor
• Headache
• Hypertension (high blood pressure)
• Nephrotoxicity (kidney damage)
• Neurotoxicity (e.g., seizures, encephalopathy)
• Hyperglycemia (high blood sugar)
• Hyperkalemia (high potassium)
• Gastrointestinal disturbances (nausea, diarrhea)
• Increased risk of infections
• Increased risk of certain cancers (lymphoma, skin cancer)
• Insomnia
• Alopecia (hair loss)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may increase the risk of liver toxicity and exacerbate gastrointestinal side effects.
• Pregnancy - Tacrolimus can cross the placenta and may be associated with adverse fetal outcomes. Use only if the potential benefit outweighs the potential risk to the fetus. Close monitoring is required.
• Breastfeeding - Tacrolimus is excreted into breast milk. Breastfeeding is generally not recommended due to potential adverse effects on the infant.
• Liver - Use with caution in patients with severe liver impairment; dose adjustments are often necessary. Regular monitoring of liver function and tacrolimus levels is crucial.
• Kidney - Tacrolimus is nephrotoxic. Close monitoring of kidney function (creatinine, GFR) is essential, and dose adjustments may be required to prevent or manage kidney injury.
• Lung - Rarely, tacrolimus has been associated with pulmonary fibrosis or pneumonitis. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.